<a href="https://laohu8.com/S/WGRX">Wellgistics Health Inc.</a> posts third quarter net loss of $33.9 million
Wellgistics Health Inc. reported a net operating loss of $33.9 million for the third quarter of 2025, compared to a net operating loss of $1.9 million for the same period in 2024. Net loss per share was $0.46 on 74.4 million weighted average shares outstanding, up from a net loss of $0.04 per share on 48.4 million weighted average shares outstanding in the third quarter of 2024. The increase in net loss was primarily attributed to higher stock-based compensation. During the period, the company focused its sales efforts on the launch of Brenzavvy for the Type 2 diabetes market and prepared for the rollout of its EinsteinRx AI pharmacy hub software. Wellgistics Health also pursued the proposed acquisition of Kare Hub Rx to enhance telepharmacy integration capabilities.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Wellgistics Health Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1105052) on November 20, 2025, and is solely responsible for the information contained therein.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。